Two decades of our focused discovery research program have provided a detailed understanding of new mechanisms that initiate and drive neurodegeneration and identified new targets for disease-modifying treatments with strong proof-of-concept data1-4. SynaptraBIO was formed to translate these discoveries into patient-centric clinical therapies.

SynaptraBIO will develop a portfolio of first in class small molecule inhibitors for the treatment of Alzheimer’s disease, Frontotemporal Dementia and related neurological conditions, building on its AI-powered Drug Discovery platform

References

1. Ittner LM, et al. Dendritic Function of Tau Mediates Amyloid-beta Toxicity in Alzheimer's Disease Mouse Models. Cell 142, 387-397 (2010).

2. Ittner A, et al. Site-specific phosphorylation of tau inhibits amyloid-beta toxicity in Alzheimer's mice. Science 354, 904-908 (2016).

3. Ittner A, Ittner LM. Dendritic Tau in Alzheimer's Disease. Neuron 99, 13-27 (2018).

4. Ittner A, et al. Reduction of advanced tau-mediated memory deficits by the MAP kinase p38gamma. Acta Neuropathol 140, 279-294 (2020).

References

This website uses cookies.